Apogee Therapeutics Inc [APGE] stock is trading at $35.50, up 8.07%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The APGE shares have gain 6.67% over the last week, with a monthly amount drifted -10.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apogee Therapeutics Inc [NASDAQ: APGE] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $95. Previously, Canaccord Genuity started tracking the stock with Buy rating on November 25, 2024, and set its price target to $89. On May 10, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $80 on the stock. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $43 on December 20, 2023. Wedbush initiated its recommendation with a Outperform and recommended $40 as its price target on August 08, 2023. In a note dated August 08, 2023, Stifel initiated an Buy rating and provided a target price of $34 on this stock.
Apogee Therapeutics Inc [APGE] stock has fluctuated between $26.20 and $63.50 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Apogee Therapeutics Inc [NASDAQ: APGE] shares were valued at $35.50 at the most recent close of the market. An investor can expect a potential return of 167.61% based on the average APGE price forecast.
Analyzing the APGE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.22 and Total Capital is -0.3. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 33.98 points at the first support level, and at 32.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.34, and for the 2nd resistance point, it is at 37.18.
Ratios To Look Out For
For context, Apogee Therapeutics Inc’s Current Ratio is 18.55. In addition, the Quick Ratio stands at 18.55 and the Cash Ratio stands at 4.96.
Transactions by insiders
Recent insider trading involved Dambkowski Carl, Chief Medical Officer, that happened on Apr 02 ’25 when 3860.0 shares were sold. Officer, CARL DAMBKOWSKI completed a deal on Apr 02 ’25 to buy 9310.0 shares. Meanwhile, Chief Medical Officer Dambkowski Carl sold 1590.0 shares on Mar 05 ’25.
